Piper Jaffray analyst William Quirk said he is incrementally more positive on Myriad Genetics (NASDAQ: MYGN) following the ACMG ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE